Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Gastric cancer (GC) is the third leading cause of cancer-related death worldwide and it mostly develops in long-standing inflammatory conditions, and Helicobacter pylori-gastritis, in particular. Despite the increasing understanding of both the phenotypic alterations and the molecular mechanisms occurring during GC multi-step carcinogenesis, no reliable biomarker is available to be reliably implemented into GC secondary prevention strategies. Multidisciplinary diagnostic approaches integrating endoscopy, serology, histology and molecular profiling currently appears as the most appropriate approach for patients' stratification into different GC risk classes.

Original publication

DOI

10.1016/j.bpg.2014.09.002

Type

Journal

Best practice & research. Clinical gastroenterology

Publication Date

12/2014

Volume

28

Pages

1043 - 1053

Addresses

Department of Medicine, DIMED, Surgical Pathology and Cytopathology Unit, University of Padua, 35100 Padua, Italy. Electronic address: massimo.rugge@unipd.it.

Keywords

Humans, Helicobacter Infections, Adenocarcinoma, Stomach Neoplasms, Precancerous Conditions, Gastritis, Risk Assessment, Biomarkers